Calliditas adds a live pivotal study - Redeye

Calliditas lead project in the clinical pipeline besides Nefecon/TARPEYO is Setanaxib targeting primary biliary cholangitis (PBC) in a pivotal phase 2b/3 study TRANSFORM. This study is now live after having randomized the first patient, and we can expect an interim read-out in H1 2023 that will further validate the potential and decide which dose will progress into phase 3.

Länk till analysen i sin helhet: https://www.redeye.se/research/832957/calliditas-adds-a-live-pivotal-study?utm_source=finwire&utm_medium=RSS